News

  • – Engineered CD47 protects T cells for enhanced antitumor immunity

    Engineered CD47 protects T cells for enhanced antitumor immunity

    SCI News highlights the recently published work by Sean Yamada-Hunter, Johanna Theruvath, and team illuminating the relationship between adoptively transferred T cells and macrophages and how two immunotherapies may work together to increase their tumor-fighting capabilities.

  • – Stanford Cancer Institute

    FOXO1 Controls CAR-T Cell Longevity

    SCI News highlights recently published work from Crystal Mackall's lab at Stanford and Evan Weber's lab at the Children’s Hospital of Philadelphia (CHOP). Alexander Doan, Katherine Mueller, Andy Chen, and team identified a protein, FOXO1, that improves the survival and function of CAR-T cells, which may lead to more effective CAR-T cell therapies and could potentially expand its use in difficult-to-treat cancers.

  • – Stanford Cancer Institute

    CAR-T Cell Therapy in Solid Tumors

    SCI News highlights two recently published papers from the Mackall lab: work by Tara Murty, Sneha Ramakrishna, and team on immune determinants of CAR-T cell therapy & work by Dorota Klysz and team on better nutrition for stronger CAR-T cells.

  • – Stanford News

    A new RNA editing tool could enhance cancer treatment

    Stanford News highlights the work by Victor Tieu and team, which found that an RNA-targeting CRISPR platform could tune immune cell metabolism without permanent genetic changes, potentially unveiling a relatively low-risk way to upgrade existing cell therapies for cancer.

  • – Nature News

    MEGA-CRISPR tool gives a power boost to cancer-fighting cells

    Nature News highlights recently published work by Victor Tieu and team describing a system that edits RNA rather than DNA, which can give new life to exhausted CAR T cells.

  • – Spotify

    Crystal Mackall Featured in PICI Podcast: From the Origins of Immunotherapy to Curing Pediatric Cancers

    In this episode of From Bench to Fireside, Crystal Mackall, MD, Center Director for the PICI (Parker Institute for Cancer Immunotherapy) Center at Stanford Medicine, talks through what led to her contributions to cancer immunotherapy, including her point of view on tackling challenging problems like pediatric cancers.

  • – Society for Immunotherapy of Cancer

    SITC Academy of Immuno-Oncology Honors Crystal Mackall as 2023 Fellow

    The Academy of Immuno-Oncology was established by SITC to honor individuals who have launched the field of cancer immunotherapy into the breakthrough cancer treatment it is today and bring together the brightest minds in the field to continue to advance SITC, the field, and the next generation of immuno-oncologists.

  • – Society for Immunotherapy of Cancer

    Alex Doan Receives 2023 SITC Abstract Travel Scholar Award

    To promote growth and achievement amongst young investigators in the field of cancer biologics and to recognize excellence in the oral abstract and poster presentations submitted to the Society for Immunotherapy of Cancer's (SITC) Annual Meeting, SITC offers the Young Investigator Awards.

  • – Stanford Medicine

    Katie Freitas Receives the Stanford Immunology Program Hugh McDevitt Award

    The Hugh McDevitt Award recognizes and awards a graduating PhD candidate in the Immunology Program for excellence in his or her doctoral dissertation research. The candidate’s doctoral dissertation research is judged by the Immunology Program’s Executive Committee to be of the highest quality in immunology research.

  • – The Mark Foundation for Cancer Research

    Stanford Team Earns the 2023 Mark Foundation Endeavor Award

    The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. The labs of Julien Sage, K. Christopher Garcia, Crystal Mackall, and Rogelio Hernández-López will harness cutting-edge immunotherapeutic approaches to develop novel therapies that activate the immune system against small-cell neuroendocrine tumors.